Talking Medicines
Latest round
- Series A
Last raised
- Nov 2020
Total raised
- $2.3M
Investors
- 3
About Talking Medicines
Founded in 2013 and headquartered in Glasgow, UK, Talking Medicines Limited focuses on leveraging AI technology to enhance healthcare marketing. The company was co-founded by Elizabeth Fairley, Jo Halliday, and Scott Crae, with Jo Halliday serving as the CEO. Talking Medicines has undergone strategic pivots to sharpen its focus on data-driven healthcare insights.Talking Medicines specializes in AI-powered healthcare marketing solutions, with its flagship product being Drug-GPT. This product employs advanced data science techniques, including Artificial Intelligence (AI), Machine Learning (ML), and Natural Language Processing (NLP), to transform large volumes of unstructured conversational data into structured, actionable insights. Its primary use cases include message alignment, persona development, and audience intelligence, allowing healthcare agencies to derive nuanced insights from publicly sourced sentiment data. The solutions are designed to enhance data-driven decision-making during pre- and post-drug launch phases, targeting healthcare professionals and organizations that require precise data analysis.Talking Medicines generates revenue through B2B transactions, offering subscription-based access to its data intelligence platform, Drug-GPT. Clients, which include healthcare agencies and pharmaceutical companies, typically engage in yearly or multi-year contracts that provide them with access to tailored AI models and insights. These subscription plans are structured to cater to varying levels of data needs, enabling clients to choose options that best fit their operational requirements. The company aims to develop new teams and agencies to better understand patient sentiments regarding their medications. These efforts are expected to enhance their existing services and meet the growing demands of healthcare agencies and professionals.
Who invested in Talking Medicines
3 investors across 2 rounds
See all investors in Talking Medicines
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Talking Medicines
Who invested in Talking Medicines?
Talking Medicines has 3 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Talking Medicines raised?
Talking Medicines has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Talking Medicines last raise money?
Talking Medicines's most recent round on record is a Series A, in Nov 2020.
What does Talking Medicines do?
Founded in 2013 and headquartered in Glasgow, UK, Talking Medicines Limited focuses on leveraging AI technology to enhance healthcare marketing.
Where is Talking Medicines headquartered?
Talking Medicines is headquartered in Glasgow, UK.
Which VCs invest in companies like Talking Medicines?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back healthcare it companies at Talking Medicines's stage. Their profiles are linked below.
VCs backing healthcare it startups at Series A
Raising like Talking Medicines? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.